In the history of GC chemotherapy, oral anti-metabolite 5-FU, as well as trastuzumab (HER2 neutralizing antibody) and platinum preparations (cisplatin-CDDP) have been adopted as first-line chemotherapy regimens for unresectable and/or recurrent GC patients (20). This evidence concerns the gene ERBB2 and gastric cancer.